Ideas
Hyundai robotics re-rating; cheap versus AutoEver.
Hyundai Motor should be viewed more seriously than Hyundai AutoEver because Atlas humanoid mass-production and partnerships with Nvidia and Google DeepMind can turn the group into an autonomous-driving and robotics platform; it is cheap, pays dividends, and has PBR re-rating room.
Avoid KOSDAQ; liquidity favors large caps.
KOSDAQ liquidity is not returning and institutions and pension funds are selling; policy support alone is insufficient, so investors should focus on large caps rather than KOSDAQ.
Trade rare earths on China-Japan curbs.
China's export restrictions toward Japan and the likelihood that the issue will not be resolved soon make rare earth and ferrite names a short-term trading vehicle.
Bitcoin is liquidity gauge; watch breakout.
Bitcoin is a key liquidity barometer: repeated failures near 94,000 dollars have hurt small and mid caps, and a breakout could revive risk appetite in KOSDAQ.
Memory NAND upcycle; Samsung/SK hynix bullish.
Jensen Huang's comments that context is the new bottleneck imply storage, NAND, and SSD must expand alongside HBM and DRAM; NAND margins are low and have room, so the memory cycle is broadening and Samsung Electronics and SK hynix should not be treated as short-term peaks.
Watch Korean entertainment on Hallyu thaw.
Korean entertainment and content shares have fallen and rebounded from lows; while earnings are still weak, gradual easing of Hallyu restrictions improves the setup for monitoring and re-entry.
Avoid refiners; oil upside limited.
Venezuela supply potential makes a large oil-price rally unlikely, so Korean refiners are unlikely to enjoy a strong refining-margin recovery.
Avoid Samyang Foods after earnings miss.
A fourth-quarter earnings miss and slowing growth mean Samyang Foods needs a new catalyst or a clear re-acceleration before the stock can resume its growth re-rating.
Avoid PCB substrate on cost, earnings risk.
PCB and substrate makers face rising gold and copper raw-material costs plus fourth-quarter earnings-shock fears and guidance cuts; Korea Circuit is an exception tied to TPU and Broadcom, but the broader substrate group should rest.
Avoid Lunit on weak medical-AI funding.
Lunit plunged after a convertible-bond fundraising fell short, showing that funding appetite for medical AI remains weak.
Buy selective semiconductor equipment with growth.
In semiconductor materials and equipment, only names with EPS growth faster than Samsung Electronics and SK hynix can outperform; he favors CMTX, Hana Micron, EO Technics, and Hanmi Semiconductor where new customers, processes, or capex can drive upside.
Watch Korean biotech into JPM conference.
The JPMorgan Healthcare conference may become the next catalyst after CES; Korean biotech has rebounded and several names are near 52-week highs, so watch event-driven news.
Korean memory semis remain in upgrade cycle.
AI memory shortage, HBM4, and DRAM price surges are driving rapid earnings upgrades; Macquarie's targets of Samsung Electronics at 240,000 won and SK hynix at 1.12 million won support the view that memory can rise further.
Hyundai group autonomous robotics re-rating continues.
Hyundai Motor Group's CES robotics and autonomous-driving partnerships with Google DeepMind and Nvidia, plus the Atlas humanoid mass-production plan and SDV roadmap, can lift the group's valuation from legacy automaker multiples.
KOSPI still cheap; EPS upgrades continue.
The KOSPI rally is driven by EPS upgrades rather than just multiple expansion; forward P/E around 10.5x is still below long-term averages, and deposits near 90 trillion won with falling rates support equities.
Hyundai Mobis robot actuator supplier play.
Hyundai Mobis is positioned as a key robot component supplier after starting actuator supply to Boston Dynamics, giving it direct exposure to the global humanoid robot parts market.
Korean shipbuilders win LNG order wave.
Korea gained shipbuilding share in a down market, and the upcoming LNG carrier order wave, with about 110 ships needed and Korea likely to win most, supports high-value order momentum alongside MRO and special-ship demand.
Buy APR on unfounded miss fears.
APR's fourth-quarter miss rumor looks unfounded; its Ulta Beauty ranking remains third, SKU count is expanding, and brokerage checks show no unusual cost issues, so the selloff was overdone.
Buy PharmaResearch on strong December sales.
PharmaResearch's fourth-quarter miss fears look overdone because December sales were very strong; the stock's sharp drop likely offers a rebound setup.
Buy Silicon2 on cheap results momentum.
Silicon2's fourth-quarter and first-quarter earnings are seen as strong and the stock is very cheap; if liquidity returns, it can rerate.
This 3PRO TV (삼프로TV) video, published January 07, 2026,
features Kim Jang-yeol, Jang Woo-jin, Park Geun-hyung
discussing 005380.KS, KOSDAQ Index, REMX, BTC, 005930.KS, 000660.KS, Korean entertainment/content sector, Korean refiners, 003230.KS, Korean PCB/substrate sector, 222800.KQ, 328130.KQ, 042700.KS, 067310.KQ, 039030.KQ, CMTX, Korean biotech sector, EWY, 012330.KS, 329180.KS, 042660.KS, 010140.KS, 278470.KS, 214450.KQ, 257720.KQ.
20 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Kim Jang-yeol,
Jang Woo-jin,
Park Geun-hyung
· Tickers:
005380.KS,
KOSDAQ Index,
REMX,
BTC,
005930.KS,
000660.KS,
Korean entertainment/content sector,
Korean refiners,
003230.KS,
Korean PCB/substrate sector,
222800.KQ,
328130.KQ,
042700.KS,
067310.KQ,
039030.KQ,
CMTX,
Korean biotech sector,
EWY,
012330.KS,
329180.KS,
042660.KS,
010140.KS,
278470.KS,
214450.KQ,
257720.KQ
